Financial Data and Key Metrics Changes - The company reported total revenue of $110.3 million for Q3 2025, a 12% increase compared to $98.2 million in Q3 2024 [20] - Product revenue reached $105.5 million, representing a 15% year-over-year growth [4] - The gross-to-net deduction improved to approximately 31% for Q3 2025, slightly better than Q2 [20] Business Line Data and Key Metrics Changes - IBSRELA generated $78.2 million in revenue during Q3 2025, marking a 92% increase year-over-year [5][20] - XPHOZAH achieved $27.4 million in revenue, a 9% increase compared to Q2 2025 [6][21] - Non-cash royalty and commercial milestone revenue was recorded at $4.8 million, significantly higher than previous quarters [22] Market Data and Key Metrics Changes - The company noted a strong demand for IBSRELA, with record highs in new writers and total writers, indicating growth in both depth and breadth of writing [11][12] - XPHOZAH saw growth in total dispenses, including increased volume for both paid and patient-assisted prescriptions [18] Company Strategy and Development Direction - The company is focused on four key priorities: accelerating IBSRELA's momentum, executing on the XPHOZAH strategy, building a pipeline, and delivering strong financial performance [4] - The announcement of RDX 10531, a next-generation NHE3 inhibitor, marks a significant milestone in reinvigorating the company's pipeline [6][7] - The company aims to leverage its expertise and resources to unlock value and expand its product offerings [9] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the continued momentum of IBSRELA and raised revenue guidance for the year to between $270 million and $275 million [6][21] - The management team highlighted the importance of addressing unmet needs in the IBS-C and CKD markets, emphasizing the potential for future growth [19][26] - The company is optimistic about the long-term growth prospects for both IBSRELA and XPHOZAH, citing strong commercial execution and market demand [19][76] Other Important Information - The company ended Q3 2025 with a strong balance sheet, including $242.7 million in cash, cash equivalents, and short-term investments [24] - The company welcomed a new Chief Financial Officer, Suhong Leitner, who is expected to bring strategic expertise to the team [10] Q&A Session Summary Question: What are the plans for increasing front-line share for IBSRELA? - Management acknowledged the challenge of competing with LINZESS for front-line share but emphasized the organic growth and satisfaction among prescribers and patients [28][32] Question: What indications are being considered for RDX 10531? - Management indicated that while there are potential broad indications, it is premature to discuss specifics until initial development steps are completed [29][30] Question: What factors could impact the guidance for IBSRELA? - Management expressed confidence in their strategy and the high unmet need in the IBS-C market, which supports their revenue guidance [42][43] Question: What are the growth strategies for XPHOZAH? - Management highlighted the importance of driving clinical conviction among nephrologists and ensuring patient access through Ardelyx Assist [49][56] Question: What are the potential tailwinds or headwinds for 2026? - Management is optimistic about tailwinds for both IBSRELA and XPHOZAH, anticipating improved market conditions as they emerge from current challenges [75][76]

Financial Data and Key Metrics Changes - Total revenue for Q3 2025 was reported at $1.08 billion, reflecting a year-over-year growth of approximately 2% excluding China, and was above the guidance range [6][18] - Non-GAAP operating margin expanded by 190 basis points to 24.5%, and non-GAAP diluted EPS increased to $1.34, representing an 18% year-over-year growth [18][24] - Greater China revenue was $52 million, with overall revenue growth outside of China being a significant milestone [18][25] Business Line Data and Key Metrics Changes - Sequencing consumables revenue was $747 million, roughly flat year-over-year, but up about 3% excluding China [18][22] - Clinical business saw double-digit revenue growth outside of China, driven by comprehensive genomic profiling and sequencing-intensive applications [18][22] - Research consumable sales declined by high single digits outside of China due to funding uncertainty and pricing dynamics [18][22] Market Data and Key Metrics Changes - The transition to the NovaSeq X platform progressed significantly, with approximately 78% of volumes and 51% of revenue in Q3 being sequenced on X [19][20] - Total sequencing GB output on connected high and mid-throughput instruments grew at a rate of more than 30% year-over-year, primarily driven by clinical demand [21] - The instruments business in Greater China experienced a decline of approximately 54% due to export restrictions [22] Company Strategy and Development Direction - The company is focusing on three strategic pillars: growing the core sequencing business, scaling into multi-omics, and expanding services, data, and software capabilities [9][12] - The launch of Illumina Protein Prep and the five-base solution are part of the strategy to enhance multi-omics capabilities [11][12] - The company aims to achieve high single-digit revenue growth and 20% non-GAAP operating margins by 2027, excluding Greater China [16][27] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the clinical business as the primary driver of revenue growth, with expectations for a gradual return to growth in the research segment [15][16] - The company remains cautious about the regulatory environment in China but is encouraged by the resilience shown in that market [31] - Management highlighted the importance of customer feedback in shaping future product offerings and maintaining competitive advantage [14][45] Other Important Information - The company has increased its revenue guidance for Greater China by $20 million to approximately $220 million for the year [25] - Non-GAAP operating margin guidance has been raised by approximately 60 basis points to a range of 22.75% to 23% [26] - The company ended the quarter with approximately $1.28 billion in cash and cash equivalents, with plans for continued share repurchases [24] Q&A Session Summary Question: Insights on China and 2026 outlook - Management is pleased with performance in China despite unresolved regulatory issues and is optimistic about customer relationships [30][31] Question: 2026 revenue growth framework - Management acknowledges the potential for low single-digit revenue growth in 2026, driven by clinical growth and muted research revenue [32][34] Question: Margin outlook and operational efficiency - Management is confident in further margin expansion due to disciplined cost management and operational improvements [33][35] Question: Consumables growth and market dynamics - The growth in consumables was primarily driven by clinical demand, with no significant pull forward from academic or government segments [37][38] Question: Competitive landscape and market pressures - Management views competition positively, emphasizing Illumina's multi-dimensional value proposition over single-dimensional competition [44][45] Question: Future instrument placements and market trends - Management expects stable instrument placements moving forward, supported by ongoing demand in clinical and research applications [46][47] Question: Research market dynamics and funding predictability - Management notes that predictability in grant funding is crucial for research spending, with ongoing monitoring of the funding environment [60]

Papa, President and Chief Executive Officer, who will provide an update on the company's transformation plan and highlight key results. And Richard S. Lindahl, EVP and Chief Financial Officer, will provide details on the third quarter and year-to-date 2025 financial results as well as provide an update on full-year 2025 guidance. Joseph C. Papa will conclude by discussing the company's business performance and key catalysts for growth followed by Q&A. Finally, for the benefit of those who may be listening t ...

Core Viewpoint - Rosen Law Firm is investigating potential securities claims on behalf of shareholders of Soleno Therapeutics, Inc. due to allegations of materially misleading business information issued by the company [1] Group 1 - The investigation is focused on the potential impact of misleading information on the investing public [1] - Shareholders who purchased Soleno Therapeutics securities may be entitled to compensation without any out-of-pocket fees or costs [1]

NEW YORK, Oct. 30, 2025 (GLOBE NEWSWIRE) -- The Gross Law Firm issues the following notice to shareholders of MoonLake Immunotherapeutics (NASDAQ: MLTX). Shareholders who purchased shares of MLTX during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery. CONTACT US HERE:https://securitiesclasslaw.com/securities/moonlake-loss-submission-form/?id=174508&from=3 CLASS PERIOD: March 10, ...

BEDFORD, Mass.--(BUSINESS WIRE)--Stoke Therapeutics, Inc. (Nasdaq: STOK) is a biotechnology company dedicated to restoring protein expression by harnessing the body's potential with RNA medicine and has a lead investigational medicine, zorevunersen, in development as a first-in-class potential disease-modifying treatment for Dravet syndrome. The Company today announced that management will host a webcast and conference call for analysts and investors on Tuesday, November 4, 2025, at 4:30 p.m. E. ...

This release may contain forward-looking statements that involve risks and uncertainties. Among the important factors to which our business is subject that could cause actual results to differ materially from those in any forward-looking statements are: (i) changes in the rate of growth in the markets we serve, including the proteomics market; (ii) the volume, timing and mix of customer orders among our products and services; (iii) our ability to adjust our operating expenses to align with our revenue expec ...

"I am pleased to announce that the Illumina team delivered Q325 results that exceeded the high-end of our guidance range for revenue and earnings, driven by revenue acceleration in clinical, our largest market segment," said Jacob Thaysen, Chief Executive Officer. "During the quarter, we returned to growth ex-China and are executing on our strategic pillars that support our long-range financial targets." Third quarter results | GAAP | Non-GAAP (a) | | | | | --- | --- | --- | --- | --- | | Dollars in million ...

To ask a question ahead of the presentation, please submit them to @Ginkgo on X (hashtag #GinkgoResults) or by sending an e-mail to [email protected]. About Ginkgo BioworksGinkgo Bioworks builds the tools that make biology easier to engineer for everyone. Ginkgo R&D Solutions delivers customizable R&D packages—such as protein engineering, nucleic acid design, and cell-free systems—giving partners a comprehensive way to accelerate innovation across therapeutics, diagnostics, & manufacturing. Ginkgo Automati ...

CAMBRIDGE, Mass., Oct. 30, 2025 (GLOBE NEWSWIRE) -- Relay Therapeutics, Inc. (Nasdaq: RLAY), a clinical-stage precision medicine company transforming the drug discovery process by combining leading-edge computational and experimental technologies, will report third quarter 2025 financial results and corporate highlights after the U.S. financial markets close on Thursday, November 6, 2025. About Relay Therapeutics Relay Therapeutics (Nasdaq: RLAY) is a clinical-stage, small molecule precision medicine compan ...